Search 

MacroGenics is a leader in the development of next-generation antibody therapeutics for the treatment of cancer, autoimmune disorders, and infectious disease. Using its proprietary platforms for cancer-stem cells, bi-specific antibodies (DARTs) and Fc-optimization, the company has generated a robust pipeline of clinical and pre-clinical programs. The company has multiple research and development collaborations with major pharmaceutical companies including Les Laboratoires Servier, Boehringer Ingelheim and Pfizer, Inc.

Mallinckrodt, the pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions.  Covidien announced last December that they are spinning off Mallinckrodt into a stand-alone company, a process that is expected to be completed in mid-2013.  Mallinckrodt is the largest US supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. It is also the largest US supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals and contrast media and delivery systems.  Sales in 2011 were $2.0 billion. Please visit www. mallinckrodt.com to learn more about our business.  The company’s branded pharmaceuticals portfolio includes EXALGO® (hydromorphone HCl) Extended-Release Tablets (CII) and PENNSAID® (diclofenac sodium topical solution) 1.5% w/w.  In June 2012, Mallinckrodt entered into agreements with Horizon Pharma and Zogenix Inc. to co-promote their branded pharmaceuticals for rheumatoid arthritis and acute migraine, respectively.  In August 2012, the FDA approved the 32 mg tablet strength of EXALGO® (hydromorphone HCI) Extended-Release Tablets (CII).  Mallinckrodt is primarily pursuing acquisition or licensing deals for pharmaceuticals which are either in late stage development or are approved for commercialization.

MannKind’s patient-focused oral inhalation drug delivery technologies include a dry powder formulation capability coupled with an innovative, elegant, breath-powered delivery device. We are applying these technologies to facilitate partnered drug development programs for proprietary compounds.

MannKind has numerous collaborations across therapeutic areas that demonstrate the efficacy and safety of the technologies. Patients self-administer these dry powder formulations with small, easy-to-use, breath-powered inhalers. Following inhalation, drugs are absorbed very rapidly, essentially mimicking intra-arterial administration. MannKind has evaluated this versatile pulmonary drug delivery platform across multiple therapeutic areas, including diabetes, metabolism, respiratory disease, osteoporosis and pain.

For companies interested in exploring the feasibility of a Technosphere formulation using their own active pharmaceutical ingredient (API), MannKind offers a feasibility evaluation. These evaluations involve preparation and characterization of API/Technosphere formulations. These powders are tested for performance in MannKind’s inhalers. Additionally, MannKind works with the partner to test these powders in relevant nonclinical PK/PD models. These studies can often been completed within 6 months. 

MannKind seeks to establish partnerships to build therapeutic programs of significant clinical and commercial value. Whether through strategic alliances, licensing arrangements and/or research collaborations, MannKind's partnering approach is based on a flexible, creative methodology designed to establish mutually beneficial relationships that are positioned to capture upside potential beyond what either partner could achieve individually.

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration (FDA) reviewed the New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company received a Complete Response letter with respect to this NDA. MAP Pharmaceuticalshas entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found athttp://www.mappharma.com.

Meda is a global specialty pharma company with products in over 120 countries worldwide and $1.9BUSD in sales.

Meda's primary growth strategy is search and acquire focusing on acquisitions aligned with our current verticals (allergy/respiratory; women and men's health; dermatology (EU); cardiovascular (EU); and pain and inflammation).

We tend towards low risk investments, hence, late stage products (e.g., successful completion of a Phase III) or marketed products. We avoid 505(b)(2) products unless there is a clear unmet need that is met by a highly differentiated product.

Metanomics Health, a BASF group company, is the world leading company offering targeted and non-targeted metabolite profiling to healthcare customers in industry and academia. We serve pharma, nutrition and diagnostics customers, making them more successful through biomarker identification and validation across a broad range of applications.

In parallel to our third party service business we are funding and conducting a comprehensive diagnostic biomarker program in the areas of cardio-metabolic diseases, multiple sclerosis and various oncology indications, addressing open questions of high and unmet medical need.

Biomarkers covering disease diagnosis, mechanism of drug toxicity, mechanism of action and drug efficacy are increasingly needed in the preclinical and clinical setting for better evaluation of novel chemical entities including target validation and tailor-made treatment regimens.

Our non-biased broad profiling platform as well as the hypothesis-driven targeted metabolomics platforms have the potential for providing novel biomarkers of disease and drug efficacy and are routinely incorporated into biomarker discovery and validation studies.

We enhance contextualization of our reproducible and robust metabolic signatures via integration with data from other “-omics” platforms such as transcriptomics or proteomics. In our systems biology approach we are linking known metabolites and genes to relevant pathways and phenotypes, i.e. mapping genotype to phenotype.

Our customers´ personalized medicines and nutrition solutions are guided by differentiated and robust metabolite biomarker signatures, thus making sure that the right intervention is selected for the right person at the right time.